Truist Securities raises Hinge Health price target to $85

0 min read | Published on 11 Jun 2026, 08:55 PM |Updated on 11 Jun 2026, 08:55 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Truist Securities analyst Jailendra Singh maintained a Buy rating on Hinge Health and raised the price target to $85 from $79, signaling confidence in the company's valuation.

*this image is generated using AI for illustrative purposes only.

Truist Securities analyst Jailendra Singh has maintained a Buy rating on Hinge Health while raising the price target to $85 from $79. The adjustment reflects an updated valuation outlook for the digital health company.

Rating and Target Details

The research note reaffirms the positive stance on Hinge Health shares. The new price target of $85 represents an increase over the prior target of $79.

Metric	Value
Rating	Buy
Previous Price Target	$79
New Price Target	$85

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors are driving the updated valuation outlook for Hinge Health?

How might Hinge Health's market position evolve in the competitive digital health landscape?

What upcoming milestones or product launches could further impact Hinge Health's stock performance?

Barclays raises Hinge Health price target to $70

0 min read | Published on 11 Jun 2026, 07:19 PM |Updated on 11 Jun 2026, 07:19 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Barclays analyst Saket Kalia maintains an Overweight rating on Hinge Health and raises the price target to $70 from $62, signaling confidence in the company's growth prospects.

*this image is generated using AI for illustrative purposes only.

Barclays analyst Saket Kalia has maintained an Overweight rating on Hinge Health (NYSE: HNGE) and raised the price target to $70 from $62. The revised target indicates a positive outlook on the company's future performance.

Rating and Target Details

The decision to upgrade the price target comes as Hinge Health continues to strengthen its position in the digital health market. The Overweight rating suggests that the stock is expected to outperform the broader market.

Metric	Value
Rating	Overweight
Previous Price Target	$62
New Price Target	$70

Analyst Commentary

Saket Kalia's revised price target highlights the potential for significant upside in Hinge Health's stock. The company's focus on musculoskeletal care and digital therapy solutions remains a key driver of this optimistic view.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific market trends or competitive advantages justify the increased price target for Hinge Health?

How might Hinge Health's focus on musculoskeletal care influence its growth trajectory in the digital health sector?

What are the potential risks or challenges that could impact Hinge Health's ability to meet the revised $70 target?